financetom
Business
financetom
/
Business
/
Burger King Parent Restaurant Brands Gains After Q2 Results - Revenue Shines Amid Bold Future Plans
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Burger King Parent Restaurant Brands Gains After Q2 Results - Revenue Shines Amid Bold Future Plans
Aug 8, 2024 8:49 AM

Restaurant Brands International Inc. ( QSR ) shares are trading higher after the company reported second-quarter results.

The company reported adjusted earnings per share of 86 cents, missing the analyst consensus of 87 cents.

The company reported quarterly revenues of $2.08 billion, beating the street view of $2.026 billion.

Consolidated comparable sales rose by 1.9%, and net restaurants grew by 4.0% compared to the previous year. System-wide sales increased by 5.0% year-over-year.

Income from operations was $663 million, up from $554 million last year, while net income rose to $399 million from $351 million.

Adjusted operating income grew 9.3% organically to $632 million, the company said.

Also Read: Asia Mixed, Europe Markets Dip; Crude Falls Below $75 And Dollar Slips – Global Markets Today While US Slept

On April 30, 2024, Burger King unveiled its Royal Reset 2.0 program and plans to invest an additional $300 million in remodels from 2025 to 2028. Alongside the initial Reclaim the Flame investment and the remodeling of 600 recently acquired Carrols restaurants, the company aims to achieve 85% to 90% modern image by 2028.

Outlook: For 2024, the company continues to expect consolidated capital expenditures, tenant inducements and incentives (excluding RH) of approximately $300 million.

Restaurant Brands continues to expect, on average, from 2024 to 2028, its long-term guidance, which includes a 3%+ increase in comparable sales, a 5%+ growth in net restaurants, and an 8%+ rise in system-wide sales, with adjusted operating income expected to grow at least as fast as system-wide sales.

Price Action: QSR shares are trading higher by 3.43% to $72.94 at last check Thursday.

Read Next:

Move Over Yen, Yuan Carry Trades Could Be Next Ticking Bomb, Warns Strategists: ‘But It’s Below The Danger Levels We Monitor’

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump
Apr 26, 2024
10:56 AM EDT, 04/26/2024 (MT Newswires) -- Biodexa Pharmaceuticals ( BDRX ) said Friday it has signed a deal with Emtora Biosciences for the exclusive, global rights for eRapa, a phase 3-ready drug to treat familial adenomatous polyposis, an inherited condition that affects the gastrointestinal tract. Shares of the company rose more than 81% in recent Friday trading. The license...
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
Apr 26, 2024
11:00 AM EDT, 04/26/2024 (MT Newswires) -- Amgen ( AMGN ) said Friday it will submit a marketing authorization application to the European Medicines Agency for the teprotumumab medicine to treat moderate to severe thyroid eye disease in adults. Teprotumumab is approved for thyroid eye disease treatment in the US, Brazil and Saudi Arabia under the brand name Tepezza, the...
Update: AppFolio Swings to Q1 Adjusted Earnings, Revenue Rises; Lifts 2024 Revenue Guidance; Shares Climb
Update: AppFolio Swings to Q1 Adjusted Earnings, Revenue Rises; Lifts 2024 Revenue Guidance; Shares Climb
Apr 26, 2024
11:01 AM EDT, 04/26/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph) AppFolio ( APPF ) shares were up more than 16% in recent trading on Friday, a day after the company posted stronger-than-expected Q1 earnings and raised 2024 revenue guidance. The company reported late Thursday it swung to Q1 adjusted earnings of $1.05...
Update: ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17%
Update: ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17%
Apr 26, 2024
11:01 AM EDT, 04/26/2024 (MT Newswires) -- (Updates to include recent stock movement in the headline and first paragraph.) ResMed ( RMD ) shares rose by more than 17% in recent Friday trading after the company reported fiscal Q3 non-GAAP earnings of $2.13 per diluted share, up from $1.68 a year earlier. Analysts surveyed by Capital IQ expected $1.91. Revenue...
Copyright 2023-2026 - www.financetom.com All Rights Reserved